The ARHINASD (Allergic Rhinitis in Pediatric Subjects With Nasal Septum Deviation) Project
"ASSOCIATION BETWEEN NASAL SEPTUM DEVIATION AND ALLERGIC RHINITIS IN PEDIATRIC AGE: The ARHINASD (Allergic Rhinitis in Pediatric Subjects With Nasal Septum Deviation) Project"
1 other identifier
observational
69
1 country
2
Brief Summary
Allergic rhinitis is one of the most common inflammatory conditions of the upper airway mucosa, especially in the pediatric population with a prevalence of approximately 25%. It is among the most common chronic inflammatory diseases globally and is caused by IgE-mediated reactions to inhaled allergens, often co-occurring with asthma and causing severe burdens and disabilities worldwide. Allergic rhinitis can in fact seriously compromise the quality of life, significantly influencing school performance, social life and the quality of sleep. It is known that the most common symptoms characterizing allergic rhinitis (itching of the nose, sneezing, rhinorrhea and nasal/sinus obstruction) are partly overlapping with those due to a condition of deviation of the nasal septum and a recent study has shown how 87 % of patients with persistent allergic rhinitis are affected by at least 1 of the 7 types of nasal septum deformity. Deviation of the nasal septum is a very frequent anatomical disorder and is present in up to 48% of children and adolescents in the general population. The deviation narrows the affected nostril canal, reducing the flow of air that passes through the nostrils, predisposing to chronic mucosal inflammation with inflammatory infiltrate and in turn increasing the risk of developing chronic rhinitis and sinusitis. There are no data in the literature that correlate nasal septum deviation with an increased risk of developing allergic rhinitis. Given these premises, the ARHINASD (Allergic Rhinitis in pediatric topics with Nasal Septum Deviation) study was designed with the primary objective of evaluating the presence of allergic rhinitis in a sample of patients with and without deviation of the nasal septum.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
November 15, 2023
CompletedFirst Posted
Study publicly available on registry
November 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2024
CompletedSeptember 23, 2025
September 1, 2025
1 year
November 15, 2023
September 19, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Presence of allergic rhinitis
Complete clinical and anamnestic evaluation and allergy screening test (Skin-Prick Test).
12 months
Secondary Outcomes (5)
Total IgE of nasal wash supernatant
12 months
Cytokines (IL-13, IL-9, IL-33, IL-5, INFγ, β-defensin, IL-17, TNFα) of nasal wash supernatant
12 months
Quality of life questionnaire
12 months
Peak inspiratory nasal flow
12 months
Nasal cytology
12 months
Study Arms (2)
Patients with nasal septum deviation
Patients without nasal septum deviation
Interventions
Data collection
Eligibility Criteria
Caucasian children of both sexes aged between 6 and 14 with and without suspected deviation of the nasal septum observed at Pediatrics Section of Department of Translational Medical Sciences (University of Naples Federico II), University of Calabria (Department of Pharmacy, Health and Nutrition Sciences) and Otorhinolaryngology Unit, Penne Hospital, ASL of Pescara
You may qualify if:
- Caucasian ethnicity
- both sexes
- age between 6 and 14 years
- written informed consent.
You may not qualify if:
- Non-Caucasian ethnicity
- Age \<6 and \>14 years
- Concomitant presence of:
- chronic diseases
- malignancies
- immunodeficiency
- chronic infections
- autoimmune diseases
- chronic inflammatory intestinal diseases
- celiac disease
- genetic diseases
- metabolic diseases
- cystic fibrosis
- chronic pulmonary diseases
- malformations of the cardiovascular system
- +11 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Department of Traslational Medical Science - University of Naples Federico II
Naples, 80131, Italy
University of Naples Federico II
Naples, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor, PhD, Professor
Study Record Dates
First Submitted
November 15, 2023
First Posted
November 18, 2023
Study Start
January 1, 2023
Primary Completion
January 1, 2024
Study Completion
July 1, 2024
Last Updated
September 23, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share